Palleon Pharmaceuticals has dosed the first subject in the randomised Phase II trial of E-602 (HLX79), a first-in-class human sialidase enzyme therapeutic, in conjunction with Henlius’ Hanlikang ...
Considering the advancement in the diagnosis and treatment of glomerular disease, we formed a Glomerulonephritis Board (GN Board) at Cleveland Clinic that brings together key medical specialists.
From the Medical Service, Mt. Sinai Hospital, New York City. Read before the Section on Internal Medicine, New York Academy of Medicine, April 16, 1929. Moschcowitz — Associate Physician, Mt. Sinai ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results